Industry Spotlight  |
Drug Formulation

Kurma Partners to Collaborate with Samsung Biologics for the Development and Manufacture of Biologics Drugs

Edited by Tom Cohen |
24 October 2023
Samsung Biologics will develop and manufacture drugs for Kurma’s portfolio companies, including by providing CMC drug development.

South Korean contract development and manufacturing organization (CDMO) Samsung Biologics and European venture capital firm Kurma Partners have announced that they are set to enter into a collaboration.

The strategic partnership will see Samsung Biologics develop and manufacture drugs for Kurma’s portfolio companies, including by providing chemistry, manufacturing, and control (CMC) development.

This development will entail streamlining the journey from gene identification to filing for an investigational new drug (IND). Furthermore, it is hoped that this will hasten the pipeline from lead candidate selection to clinical testing of new drugs.


Samsung Biologics is an end-to-end CDMO which offers solutions from cell line development to final aseptic fill and finish as well as laboratory testing support. In the agreement, Kurma gets access to Samsung Biologics’ facilities, technology platform and knowledge of CMC development. John Rim, President and CEO of Samsung Biologics, said:

“With our in-depth knowledge on effective scale-up strategy and a diverse portfolio of proprietary platform technologies, we are looking forward to providing robust CMC solutions to reduce uncertainties, ensure regulatory compliance, and ultimately maximize manufacturing efficiency for our clients.”

Kurma Partners is based in Paris and Munich and finances a wide selection of healthcare and biotech companies with the funds that they provide to the life sciences industry. Daniel Parera, Partner at Kurma Partners, said: “We are very excited to partner with Samsung Biologics, a world-leading CDMO with capabilities of highest industry standards. This will greatly benefit our portfolio of Kurma Biofunds and Kurma Growth Opportunities Fund in advancing large molecule biologics from discovery to the market.”

Get your weekly dose of industry news and announcements here, or head over to our Formulation portal to catch up with the latest advances in manufacture and therapeutic delivery. If you’d like to learn more about our upcoming Formulation and Delivery event, click here to download an agenda or register your interest.

How would you rate this content?

Share this article

Sign up for our monthly Formulation & Delivery Newsletter

You may also be interested in...

Industry Spotlight
Advancements in Small Molecule Drug Formulation has witnessed remarkable progress in recent years including nanotechnology and new improved drug delivery systems.
13 November 2023
Industry Spotlight
Before joining Amgen, Dr Tukra got his PhD from Purdue University in Industrial and Physical Pharmacy. While at Purdue he also worked at LyoHUB as an advisor and researcher in industrial and academic projects.
23 October 2023

Share this article

Join our Formulation & Delivery mailing list

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Formulation & Delivery